首页> Toxicologic pathology> Scientific and Regulatory Policy Committee Points to Consider: Fixation, Trimming, and Sectioning of Nonrodent Eyes and Ocular Tissues for Examination in Ocular and General Toxicity Studies.

Scientific and Regulatory Policy Committee Points to Consider: Fixation, Trimming, and Sectioning of Nonrodent Eyes and Ocular Tissues for Examination in Ocular and General Toxicity Studies.

导出原文传递

翻译打印收藏纠错

第一作者： Helen S,Booler

第一单位： Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Switzerland.

作者： Helen S,Booler ^[1] ; Typhaine,Lejeune ^[2] ; Steven,Sorden ^[3] ; Margarita M,Gruebbel ^[4] ; Kenneth A,Schafer ^[5] ; Brian,Short ^[6] ; Cindy,Farman ^[7] ; Meg Ferrell,Ramos ^[8] ; Bindu,Bennet ^[9] ; Krishna,Yekkala ^[10] ; Elke-Astrid,Atzpodien ^[1] ; Oliver C,Turner ^[11] ; Jaqueline,Brassard ^[12] ; George,Foley ^[13]

作者单位： Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Switzerland. ^[1] Charles River Montreal ULC, Senneville, Quebec, Canada. ^[2] Labcorp Drug Development, Madison, WI, USA. ^[3] Experimental Pathology Laboratories, Inc. (EPL, Inc.), Research Triangle Park, NC, USA. ^[4] Greenfield Pathology Services, Inc., Greenfield, IN, USA. ^[5] Brian Short Consulting, LLC, Laguna Beach, CA, USA. ^[6] StageBio, Mount Jackson, VA, USA. ^[7] AbbVie, Inc., North Chicago, IL, USA. ^[8] Relay Therapeutics, Cambridge, MA, USA. ^[9] Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA, USA. ^[10] Novartis, Novartis Institutes for BioMedical Research, Preclinical Safety, East Hanover, NJ, USA. ^[11] Independent Consultant, Tustin, CA, USA. ^[12] Kalamazoo, MI, USA. ^[13]

关键词 area centralis eye fovea macula retina toxicity studies visual streak